<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04684875</url>
  </required_header>
  <id_info>
    <org_study_id>CTP1078</org_study_id>
    <nct_id>NCT04684875</nct_id>
  </id_info>
  <brief_title>Quality of Life Impact of Chronic Rhinitis Treatment With Aerin Medical Device</brief_title>
  <official_title>A Prospective, Multi-center, Non-Randomized Study to Evaluate the Quality of Life Impact and Symptoms After Treatment Using Low Power Radiofrequency Energy Applied to the Posterior Nasal Nerve Area for Symptomatic Relief of Chronic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aerin Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aerin Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of long-term (2-year) quality of life and symptoms after chronic rhinitis&#xD;
      treatment with the Aerin InSeca/RhinAer Stylus&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, non-randomized, multicenter follow-up study to collect long-term data&#xD;
      on a cohort of patients who participated in the Aerin Medical TP668 study, &quot;Clinical&#xD;
      Evaluation of Low Power Radiofrequency Energy Applied to the Posterior Nasal Nerve Area for&#xD;
      Symptomatic Relief of Chronic Rhinitis&quot;. The study will be conducted in a maximum of 5&#xD;
      centers that participated and enrolled patients in the TP668 study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 19, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 10, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline rTNSS</measure>
    <time_frame>24 months</time_frame>
    <description>Mean change in reflective Total Nasal Symptom Score (rTNSS) from baseline. The TNSS is an instrument used to collect patient self-rated severity of rhinorrhea, nasal congestion, nasal itching and sneezing. In this study, a reflective score will be collected, in which the subject will be asked to evaluate symptom severity over the preceding 12 hours. Symptom severity is rated on a 4-point scale of 0 (absent symptoms), 1 (mild symptoms), 2 (moderate symptoms, or 3 (severe symptoms), with the total score therefore ranging from 0 to 12. A negative change reported for the change from baseline indicates an improved outcome.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Chronic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Long-Term Study Subjects</arm_group_label>
    <description>All subjects who were treated with the Aerin Medical InSeca/RhinAer Stylus in the 50-subject TP668 interventional study, who consent to continue to provide quality of life data.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radiofrequency Stylus</intervention_name>
    <description>Low power radiofrequency energy delivered to the posterior nasal nerve area</description>
    <arm_group_label>Long-Term Study Subjects</arm_group_label>
    <other_name>Aerin Medical Device</other_name>
    <other_name>InSeca Stylus</other_name>
    <other_name>RhinAer Stylus</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who completed the 52-week follow-up visit of Aerin Study TP668 and consent to&#xD;
        provide long-term quality of life and symptom information.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Received treatment for chronic rhinitis in Aerin Study TP668&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwilling to participate in this long-term study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Wolf, MD</last_name>
    <role>Study Director</role>
    <affiliation>Aerin Medical, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Colorado ENT and Allergy</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced ENT and Allergy</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont ENT Associates</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Worth ENT</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENT and Allergy Associates of Texas</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 22, 2020</study_first_submitted>
  <study_first_submitted_qc>December 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2020</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic rhinitis</keyword>
  <keyword>Posterior nasal nerve</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

